Circulating MicroRNA-26a in Plasma and Its Potential Diagnostic Value in Gastric Cancer.
Circulating MicroRNA-26a in Plasma and Its Potential Diagnostic Value in Gastric Cancer.
复制标题
血浆中循环的 MicroRNA-26a 及其对胃癌的潜在诊断价值
DOI：
10.1371/journal.pone.0151345
复制
发表时间：
2016
期刊：
影响因子：
3.7
通讯作者：
Zhang Z
中科院分区：
文献类型：
--
作者：
Qiu X;Zhang J;Shi W;Liu S;Kang M;Chu H;Wu D;Tong N;Gong W;Tao G;Zhao Q;Qiang F;Zhu H;Wu Q;Wang M;Zhang Z
在过去的几十年里，大量的研究已经提供了循环microRNAs （miRNAs）作为癌症诊断的非侵入性生物标志物的可能性。本研究的目的是检测胃癌（GC）患者组织和血浆中循环mirna的水平，并评估其诊断价值。方法收集85例胃癌患者的组织标本。收集285例胃癌患者和285例对照组的血浆样本。用Agilent Human miRNA Microarray和TaqMan low density array （TLDA）过滤差异表达的miRNA，合并样本，然后进行定量逆转录聚合酶链反应（qRT-PCR）验证。构建受试者工作特征（ROC）曲线来评估mirna的诊断准确性。比较不同临床分期胃癌患者血浆miR-26a水平。结果4种mirna （miR-26a、miR-142-3p、miR-148a和miR-195）在胃癌患者组织和血浆中的水平与对照组相比一致下降，构建ROC曲线显示miR-26a的ROC曲线下面积（AUC）最高，为0.882。此外，miR-26a在不同临床特征的GC患者血浆中稳定检测。结论血浆miR-26a可能是一种新的、稳定的胃癌标志物。
Background In the past decades, a good deal of studies has provided the possibility of the circulating microRNAs (miRNAs) as noninvasive biomarkers for cancer diagnosis. The aim of our study was to detect the levels of circulating miRNAs in tissues and plasmas of gastric cancer (GC) patients and evaluate their diagnostic value. Methods Tissue samples were collected from 85 GC patients. Plasma samples were collected from 285 GC patients and 285 matched controls. Differentially expressed miRNAs were filtered with by Agilent Human miRNA Microarray and TaqMan low density array (TLDA) with pooled samples, followed by the quantitative reverse transcription polymerase chain reaction (qRT-PCR) validation. Receiver operating characteristic (ROC) curves were structured to evaluate the diagnostic accuracy of the miRNAs. The plasma level of miR-26a in GC patients of different clinical stages was compared. Results Four miRNAs (miR-26a, miR-142-3p, miR-148a, and miR-195) revealed coincidentally decreased levels in tissue and plasma of the GC patients compared with controls, and ROC curves were constructed to demonstrate that miR-26a had a highest area under the ROC curve (AUC) of 0.882. Furthermore, miR-26a was stably detected in the plasma of GC patients with different clinical characteristics. Conclusion Plasma miR-26a may provide a novel and stable marker of gastric cancer.